Clinical Scorecard: Network Meta-Analysis of Glucagon-Like Peptide-1 Receptor Agonists, Metformin, and Inositol for Enhancing Metabolic and Anthropometric Outcomes in Women with Polycystic Ovary Syndrome

At a Glance

Key Highlights

• GLP-1 receptor agonists combined with metformin produced the greatest reductions in body weight and BMI among women with PCOS
• GLP-1 monotherapy significantly reduced waist circumference
• No treatment demonstrated a statistically significant effect on HOMA-IR
• The analysis included 16 RCTs evaluating the efficacy of GLP-1 receptor agonists, metformin, and myoinositol
• Further long-term and head-to-head RCTs are needed for broader outcome evaluations

Guideline-Based Recommendations

Diagnosis

• PCOS is diagnosed based on clinical and/or biochemical signs of hyperandrogenism, ovulatory dysfunction, and polycystic ovaries.

Management

• Lifestyle modification is recommended as first-line treatment for all women with PCOS.

Monitoring & Follow-up

• Regular monitoring of metabolic parameters is advised for women with PCOS undergoing treatment.

Risks

• Women with PCOS are at increased risk for type 2 diabetes, dyslipidemia, and cardiovascular disease.

Patient & Prescribing Data

Women diagnosed with PCOS experiencing metabolic dysfunction

GLP-1 receptor agonists combined with metformin are effective for weight and BMI reduction.

Clinical Best Practices

• Incorporate lifestyle interventions alongside pharmacologic treatments for optimal management of PCOS.
• Consider GLP-1 receptor agonists for patients needing significant metabolic improvement.

Related Resources & Content

• Systematic review registration